IQVIA Holdings Inc
Company Profile
Business description
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Contact
2400 Ellis Road
DurhamNC27703
USAT: +1 919 998-2000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
90,000
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
stocks
This ASX stock’s bubble has well and truly burst
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,222.30 | 6.20 | -0.07% |
| CAC 40 | 7,709.81 | 133.23 | -1.70% |
| DAX 40 | 24,152.87 | 120.25 | -0.50% |
| Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
| FTSE 100 | 9,265.80 | 55.60 | -0.60% |
| HKSE | 25,521.73 | 3.19 | -0.01% |
| NASDAQ | 21,544.27 | 94.98 | 0.44% |
| Nikkei 225 | 42,529.95 | 135.55 | 0.32% |
| NZX 50 Index | 12,919.78 | 38.20 | -0.29% |
| S&P 500 | 6,465.94 | 26.62 | 0.41% |
| S&P/ASX 200 | 8,953.60 | 7.60 | -0.08% |
| SSE Composite Index | 3,865.16 | 3.22 | -0.08% |